Fundraising Fox

Alex Mayweg

Investor

Managing Director at Versant Ventures

Basel, Switzerland

Writes $100K – $5M checks · typically $1.5M

About

Managing Director at Versant and head of Ridgeline Therapeutics, Versant's Basel-based Discovery Engine, with deep experience in drug discovery and medicinal chemistry. He previously served as global head of chemistry at Roche over a 14-year career and holds a Ph.D. in organic chemistry from Oxford, with post-doctoral training at Stanford and an undergraduate degree from Imperial College London.

LinkedIn ↗X / Twitter ↗

Experience

  1. Versant VenturesManaging Directorcurrent2020 — presentBasel, Basel-Town, Switzerland
  2. Versant VenturesPartner2018 — 2020Basel Area, Switzerland
  3. Versant VenturesVenture Partner2017
  4. Versant VenturesEntrepreneur in Residence2016Basel Area, Switzerland
  5. Red Ridge BioPresident of the Board of Directorscurrent2022 — presentBasel, Basel, Switzerland
  6. Serac BiosciencesPresident of the Board of Directorscurrent2022 — presentBasel, Basel, Switzerland
  7. Revelio TherapeuticsChairman of the Boardcurrent2022 — present
  8. Bright Peak TherapeuticsBoard Membercurrent2017 — present
  9. Ridgeline TherapeuticsPresident and CSOcurrent2017 — presentBasel Area, Switzerland
  10. Enterprise TherapeuticsBoard Directorcurrent2018 — presentUnited Kingdom
  11. SixPeaks BioPresident of the Board of Directors2022 — 2025Basel, Switzerland
  12. Granite BioPresident of the Board of Directors2021 — 2024Basel, Basel, Switzerland
  13. Monte Rosa TherapeuticsBoard Director2018 — 2024Basel Area, Switzerland
  14. Black Diamond TherapeuticsBoard Director2017 — 2024Basel Area, Switzerland
  15. Black Diamond TherapeuticsFounding CSO2017 — 2018Basel Area, Switzerland
  16. RocheGlobal Head of Medicinal Chemistry | Principal Leader, VP2013 — 2016Basel Area, Switzerland
  17. RocheHead of Antibiotics Disease Area (Additional Responsibility) | Senior Leader2012 — 2014Shanghai & Basel
  18. RocheSite Head of Medicinal Chemistry | Senior Leader2011 — 2013Shanghai City, China
  19. RocheSection Head in Discovery Chemistry Technologies & Metabolic Diseases | Leader2011Shanghai City, China
  20. RocheGroup Leader, Medicinal Chemistry | Principal Scientist2009 — 2011Basel Area, Switzerland

Education

  1. Stanford UniversityPost Doc, Organic Chemistry2001 — 2003
  2. University of OxfordD.Phil., Organic Chemistry1998 — 2001
  3. Imperial College LondonB.Sc., Chemistry with a Year in Industry1994 — 1998
  4. German School LondonAbitur (IB equivalent)1989 — 1994

Skills & more

Leadership9Drug Discovery99Medicinal Chemistry97Organic Synthesis71Pharmaceutical Industry51Drug Development32Infectious Diseases19Lead Change13Life Sciences40Drug Design23R&D14Organic Chemistry19
+12 moreHigh Throughput ScreeningOncologyVirologyChemistryCheminformaticsBiotechnologyLifesciencesBiochemistryNeurosciencePharmacologyHPLCBiomarkers

Languages English · French · German · Italian · Mandarin

From Alex's professional profile.

Same school

Also attended Stanford University1,575

Peter ThielCo-founder & Partner at Founders FundReid HoffmanCo-founder of LinkedIn; Partner at GreylockDavid SacksCo-founder & General Partner at Craft Ventures; former White House AI & Crypto CzarKeith RaboisManaging Director at Khosla VenturesGarry TanPresident & CEO of Y CombinatorAlfred LinPartner at Sequoia Capital

+ 1,569 more

Also attended University of Oxford687

Reid HoffmanCo-founder of LinkedIn; Partner at GreylockMichael MoritzFormer Partner at Sequoia Capital; Senior Adviser at Sequoia HeritageBrad GerstnerFounder & CEO of Altimeter CapitalDominic JacquessonInvestor at Index VenturesErin Price-WrightInvestor at Index VenturesJan HammerInvestor at Index Ventures

+ 681 more

Also attended Imperial College London295

Deji SasegbonVP, Platform & Portfolio Operations at EchoVC PartnersMadison LenormandInvestor at DaphniPauline BoucherInvestor at DaphniLoubaba El AyoubiInvestor at NorthzoneGiovanni MariggiInvestor at MedicxiFrancois PrinslooInvestor at Medicxi

+ 289 more

Shared employers

Also worked at Red Ridge Bio4

Markus EnzelbergerPartner at Versant VenturesCheryl KuaiManaging Director at Sixty Degree CapitalKenneth GriséPrincipal at Sixty Degree CapitalYi (Lily) LiManaging Director at Sixty Degree Capital

Also worked at Serac Biosciences1

Markus EnzelbergerPartner at Versant Ventures

Also worked at Ridgeline Therapeutics1

Markus EnzelbergerPartner at Versant Ventures

Also worked at SixPeaks Bio1

Markus EnzelbergerPartner at Versant Ventures

Deals · 3

Firefly Bio, Inc.Board seat

via Versant Ventures · filed Mar 2024 · $72M raise

Bright Peak TherapeuticsBoard seat

via Versant Ventures · filed Jun 2021 · $106.5M raise

Aset TherapeuticsBoard seat

via Versant Ventures · filed Jan 2018 · $12.1M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Versant Ventures

Alicia Levey
Venture Partner at Versant Ventures
Andrew Jefferson
Operating Partner at Versant Ventures
Ariel Kantor
Principal at Versant Ventures
Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Managing Director at Versant Ventures
Bill Link
Investor at Versant Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures
Brian Atwood
Managing Director at Versant Ventures

Network10

Barbara Lubash
Managing Director at Versant Ventures
Beckie Robertson
Managing Director at Versant Ventures
Bill Link
Investor at Versant Ventures
Brad Bolzon
Chairman, Managing Director at Versant Ventures
Brian Atwood
Managing Director at Versant Ventures
Carlo Rizzuto
Managing Director at Versant Ventures
Chandra Leo
Partner at HBM Partners
Clare Ozawa
Managing Director at Versant Ventures
Don Milder
Managing Partner at Versant Ventures
Erik T. Engelson
Venture Partner at Versant Ventures

Investors connected to Alex in public investor directories — a warm-intro map.